Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick McCann

Advanced Heart Failure and Transplant Cardiology Columbia, SC Medical Doctor

NPI 1487850780 CMS profile 22169

110 Gateway Corporate Blvd Ste 130, Ste 2100, Columbia, SC 29203

Open in the dashboard

General payments

$578,616

1,408 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$799,328 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patrick McCann of Columbia, SC is reported in the CMS Open Payments database as having received $578,616 across 1,408 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $799,328 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $79,667 160
2024 General $111,953 294
2023 General $104,723 308
2022 General $60,820 206
2021 General $61,786 132
2020 General $97,829 163
2019 General $61,838 145

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick McCann
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Patrick McCann were reported at $79,667. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Patrick McCann Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $61,838 $863 $224–$4,562 $163
2020 $97,829 $452 $122–$3,992 $114
2021 $61,786 $550 $159–$3,571 $132
2022 $60,820 $729 $221–$4,357 $149
2023 $104,723 $1,002 $309–$5,827 $160
2024 $111,953 $931 $273–$5,204 $164
2025 $79,667 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $245,156 631 payments
  2. CVRx, Inc. $153,222 171 payments
  3. AstraZeneca Pharmaceuticals LP $119,431 152 payments
  4. Novartis Pharmaceuticals Corporation $23,476 91 payments
  5. Janssen Pharmaceuticals, Inc $11,757 23 payments
  6. Lexicon Pharmaceuticals, Inc. $10,175 12 payments
  7. Daxor Corporation $4,066 5 payments
  8. Ancora Heart, Inc. $2,328 15 payments
  9. Boston Scientific Corporation $1,873 53 payments
  10. Medtronic, Inc. $1,029 11 payments
  11. Other $6,104 244 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $320,361 222 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $130,800 78 payments
  3. Travel and Lodging $81,642 213 payments
  4. Food and Beverage $33,521 888 payments
  5. Honoraria $12,265 5 payments
  6. Education $27 2 payments
Products named General payments · program years 2019–2025
  1. Barostim Neo System $153,222 171 payments
  2. FARXIGA $119,082 132 payments
  3. CARDIOMEMS Heart failure $96,816 237 payments
  4. CardioMEMS HF System Cardiac Arrhythmias and Heart Failure $57,171 65 payments
  5. CARDIOMEMS Structural Heart $34,370 57 payments
  6. CardioMEMS HF System Heart failure $22,774 40 payments
  7. ENTRESTO $18,379 73 payments
  8. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $14,439 114 payments
  9. XARELTO $11,757 23 payments
  10. Inpefa $10,175 12 payments
  11. Other $36,534 542 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,649

Median for Cardiology: 2,533

Drug cost

$2,212,205

Median for Cardiology: $485,213

Branded share of claims

50.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 47 $978,327
Entresto Sacubitril/Valsartan Brand 305 $340,970
Vyndaqel Tafamidis Meglumine Brand 13 $292,550
Camzyos Mavacamten Brand 25 $198,967
Farxiga Dapagliflozin Propanediol Brand 145 $138,103
Jardiance Empagliflozin Brand 145 $136,479
Eliquis Apixaban Brand 83 $64,590
Verquvo Vericiguat Brand 19 $21,700
Xarelto Rivaroxaban Brand 23 $19,609
Brilinta Ticagrelor Brand 11 $6,376

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$168,062

Medicare's payments for the services billed

Medicare patients

394

Average age 75

Services billed

3,849

163 women, 231 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 74%
Chronic kidney disease 69%
Atrial fibrillation 64%
Diabetes 60%
Arthritis 52%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Inpefa
$10,140 — —
FARXIGA
$7,134 145 —
ONPATTRO
$213 — —
VYNDAQEL
$121 13 —
VERQUVO
$106 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

1,408 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record